Wall Street analysts expect Galectin Therapeutics Inc. (NASDAQ:GALT) to report earnings per share (EPS) of ($0.14) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Galectin Therapeutics’ earnings, with estimates ranging from ($0.18) to ($0.10). Galectin Therapeutics posted earnings per share of ($0.11) in the same quarter last year, which would indicate a negative year over year growth rate of 27.3%. The company is scheduled to report its next earnings results on Tuesday, August 13th.
On average, analysts expect that Galectin Therapeutics will report full-year earnings of ($0.59) per share for the current year, with EPS estimates ranging from ($0.75) to ($0.42). For the next financial year, analysts forecast that the firm will report earnings of ($0.62) per share, with EPS estimates ranging from ($0.65) to ($0.58). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Galectin Therapeutics.
Galectin Therapeutics (NASDAQ:GALT) last released its quarterly earnings results on Wednesday, March 6th. The company reported ($0.08) earnings per share for the quarter, meeting the Zacks’ consensus estimate of ($0.08).
NASDAQ GALT traded down $0.11 during trading hours on Wednesday, reaching $4.55. 181,032 shares of the stock traded hands, compared to its average volume of 366,382. Galectin Therapeutics has a 1 year low of $3.17 and a 1 year high of $9.49.
In related news, Director Marc Rubin sold 51,185 shares of the firm’s stock in a transaction dated Friday, February 22nd. The stock was sold at an average price of $6.02, for a total value of $308,133.70. Following the sale, the director now directly owns 13,581 shares of the company’s stock, valued at $81,757.62. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard E. Uihlein bought 20,700 shares of the business’s stock in a transaction that occurred on Tuesday, April 9th. The stock was acquired at an average cost of $4.82 per share, for a total transaction of $99,774.00. Following the completion of the purchase, the director now directly owns 2,628,489 shares of the company’s stock, valued at $12,669,316.98. The disclosure for this purchase can be found here. 45.20% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of GALT. Wells Fargo & Company MN grew its stake in shares of Galectin Therapeutics by 45.7% in the third quarter. Wells Fargo & Company MN now owns 58,471 shares of the company’s stock worth $352,000 after purchasing an additional 18,336 shares during the last quarter. BlackRock Inc. boosted its position in Galectin Therapeutics by 2.3% during the 3rd quarter. BlackRock Inc. now owns 601,657 shares of the company’s stock valued at $3,616,000 after acquiring an additional 13,349 shares in the last quarter. Vanguard Group Inc. boosted its position in Galectin Therapeutics by 18.7% during the 3rd quarter. Vanguard Group Inc. now owns 1,432,576 shares of the company’s stock valued at $8,609,000 after acquiring an additional 225,822 shares in the last quarter. Vanguard Group Inc boosted its position in Galectin Therapeutics by 18.7% during the 3rd quarter. Vanguard Group Inc now owns 1,432,576 shares of the company’s stock valued at $8,609,000 after acquiring an additional 225,822 shares in the last quarter. Finally, D.A. Davidson & CO. boosted its position in Galectin Therapeutics by 4.3% during the 4th quarter. D.A. Davidson & CO. now owns 718,923 shares of the company’s stock valued at $2,466,000 after acquiring an additional 29,645 shares in the last quarter. 12.68% of the stock is currently owned by institutional investors.
Galectin Therapeutics Company Profile
Galectin Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, skin, and cancer diseases. The company's lead product candidate includes GR-MD-02 galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer.
Recommended Story: Index Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Galectin Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galectin Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.